Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on NPS Pharmaceuticals

Related NPSP
10 Biotech Stories You Might've Missed This Week
Wall Street's Wheelings And Dealings
NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog (Zacks)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on NPS Pharmaceuticals (NASDAQ: NPSP), and raised its price target from $13.00 to $15.00.

Jefferies noted, “As expected, FDA's AdComm panel voted for recommending approval of Gattex unanimously. Panel also voted favorably on NPSP's proposed REMS (10-1), supporting likely timely approval (PDUFA date, 12/30/12). With potential approval of a 2nd product Natpara in ~mid-2014, we see significant upside in NPSP shares from current levels. Reiterate Buy.”

NPS Pharmaceuticals closed on Tuesday at $10.19.

Latest Ratings for NPSP

Jan 2015JP MorganMaintainsNeutral
Jan 2015BarclaysDowngradesOverweightEqual-weight
Jan 2015Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (NPSP)

Around the Web, We're Loving...

Get Benzinga's Newsletters